Lilly's drug is the only oral treatment in a field of several injectable therapies being tested to treat high Lp(a), a risk factor for heart disease that affects one in five individuals globally ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but stock risks remain. See more on JANX.

On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...

In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals, ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.